Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Cancer Therapies

Cancer Therapies

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistent Cancers

Treatment Resistent Cancers

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Author Correction: SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.

Nature medicine·2026

Same author

Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.

Nature medicine·2026

Same author

Risk of intensive care unit admission after immune checkpoint inhibitor use in cancer.

Seminars in oncology·2026

Same author

Mature Outcomes of 61.2 Gy Concomitant Boost Thoracic Radiation Therapy in Limited-Stage Small Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538.

International journal of radiation oncology, biology, physics·2026

Same author

Early ctDNA stratifies survival in locally advanced and oligometastatic lung cancer treated with radiotherapy.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same journal

Clinical Trials and Translational Advances in Metabolic Targeting.

Cancer treatment and research·2026

Same journal

Tools and Technologies for Studying Cancer Metabolism.

Cancer treatment and research·2026

Same journal

Cancer and Immune Cells: A Metabolic Battle in the Tumor Microenvironment.

Cancer treatment and research·2026

Same journal

Biomarkers of Cancer Metabolism and Therapeutic Response.

Cancer treatment and research·2026

Same journal

Targeting Metabolism in Cancer Therapy: Inhibitors and Approaches.

Cancer treatment and research·2026

Same journal

Metabolic Reprogramming in Cancer Stem Cells.

Cancer treatment and research·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 16, 2026

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression

Published on: March 17, 2020

Multimodality Therapy for NSCLC.

Lingling Du¹, Saiama N Waqar¹, Daniel Morgensztern²

¹Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, 63110, USA.

Cancer Treatment and Research

|August 19, 2016

Summary

This summary is machine-generated.

For unresectable stage III non-small cell lung cancer (NSCLC), concurrent chemotherapy and radiotherapy is standard. The benefit of additional chemotherapy or targeted therapies in stage III NSCLC requires further investigation.

Keywords:

Chemoradiotherapy Immunotherapy Molecularly targeted therapy Stage III NSCLC

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Related Experiment Videos

Last Updated: Mar 16, 2026

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression

Published on: March 17, 2020

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Area of Science:

Oncology
Medical Research
Clinical Trials

Background:

Standard treatment for unresectable stage III non-small cell lung cancer (NSCLC) involves concurrent chemotherapy and radiotherapy.
While concurrent therapy is superior to sequential, the role of additional chemotherapy (induction or consolidation) is not well-defined.

Purpose of the Study:

To evaluate the efficacy of induction and consolidation therapies in stage III non-small cell lung cancer.
To explore the potential of targeted therapies and checkpoint inhibitors in treating unresectable stage III NSCLC.

Main Methods:

Review of current treatment strategies for stage III non-small cell lung cancer.
Analysis of ongoing clinical trials investigating novel therapeutic approaches.

Main Results:

Concurrent chemoradiotherapy is the established standard for unresectable stage III NSCLC.
Targeted therapies have shown limited success in unselected patient populations.
Ongoing trials are exploring induction erlotinib/crizotinib and consolidation checkpoint inhibitors.

Conclusions:

The optimal role for additional chemotherapy in stage III NSCLC remains an area of active research.
Future research focuses on molecularly selected patients and novel agents like checkpoint inhibitors.